Why the study?
Does doxorubicin chemotherapy cause significant myocardial damage as measured by cTnI and TVI in dogs with malignant lymphoma?
Does doxorubicin chemotherapy cause significant myocardial damage as measured by cTnI and TVI in dogs with malignant lymphoma?
Standard doses of doxorubicin in dogs with lymphoma do not appear to cause significant myocardial damage as assessed by cTnI and TVI over 12 weeks.
Answers are grounded in this paper and cite their sources.
Reassures on short-term myocardial safety with doxorubicin in canine lymphoma; leaves open longer-term or cumulative effects.
Doxorubicin has been shown to be cardiotoxic at high doses but is an efficacious chemotherapeutic agent in the treatment of canine lymphoma. Echocardiographic measurements and serum ultrasensitive cardiac troponin I (cTnI) levels were obtained before and after doxorubicin administration in 14 dogs diagnosed with lymphoma. The aim of this prospective study was to evaluate changes in cTnI concentrations and tissue velocity imaging (TVI) values in dogs with lymphoma undergoing chemotherapy with doxorubicin. A total of 182 cTnI and 1017 TVI measurements were performed. Standard echocardiographic parameters, tissue Doppler indices and cTnI concentrations did not differ at any time point within a 12-week cyclic combination protocol. In conclusion, the use of doxorubicin at standard doses in the treatment of canine lymphoma may not be associated with significant myocardial damage.
No takes yet. Share an insight, caveat, or question.
Tater et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: